MUMBAI, Nov 10 (Reuters) – Singapore’s Temasek Holdings has bought a 10.16 percent stake in Intas Pharmaceuticals, a privately-held Indian drugmaker, Intas said on Monday. Temasek bought the stake through a secondary purchase of shares from private equity firm ChrysCapital, according to the statement. The financial terms of the deal were not disclosed. Temasek, the Singapore state investor, last month agreed to invest over $80 million to buy a stake in the operator of KFC, Pizza Hut and Costa Coffee chains in India.
Industry Archives: Pharmaceuticals
MUMBAI: Promoters of Laila Nutraceuticals, an export-oriented business unit of the Andhra-based Laila Group, is in talks with global PE funds to raise around $40 million, two people with direct knowledge of the development said. The company that’s being valued at around $150 million, will look to sell up to 40 per cent stake. “The company is in talks with global PE funds to raise money. Currently, the due diligence is on,” said a person involved in the deal. Kiran Bhupatiraju, chief executive officer of Laila Nutraceuticals, did not respond to emailed queries and calls on his mobile.
Laila Nutraceuticals is part of the Laila Group with business interests across sectors such as pharmaceuticals, nutraceuticals, ayurvedic products, sugar, paper, finance, hospitality, real estate and education. It manufactures and exports herbal extracts that are key ingredients for the dietary and nutritional supplements. The firm is largely dependent on three key herbal extracts -boswellia, garcinia and gymnema – deriving over 95 per cent of its revenues from these products.
MagForce injects iron oxide nanoparticles into a patient and then vibrates them with a magnetic field to generate heat that helps kill cancer cells. It sounds like science fiction but it’s real. That’s why Peter Thiel‘s late-stage investment firm Mithril Capital just led a $15 million investment into MagForce’s new American subsidiary that values it at $65 million. Founded in 1997, MagForce is already listed on the Frankfurt stock exchange with $144 million market cap. The cash infusion will pay for the nanomedicine company to fund its development for use against more types of cancer, and the approval process in the United States. If MagForce’s NanoTherm treatment gets the greenlight in America, CEO Ben Lipps tells the company will IPO stateside.
Moscow Times June 24, 2014
U.S. healthcare firm Abbott Laboratories is to buy Russian drugmaker Veropharm for up to $495 million, giving it a manufacturing presence in a country where it has been operating for nearly 40 years, Abbott said Tuesday.
The deal bucks a drought in Russian M&A activity this year due to the country’s faltering economy and the Ukraine crisis. U.S. companies have been particularly stymied from investing here, with Washington advising top executives to steer clear of a major Russian investment forum in May.
Abbott’s purchase is the largest acquisition by a U.S. company in Russia since Philip Morris International and Japan Tobacco in December announced plans to buy stakes in cigarette distributor Megapolis for $750 million each, according to Thomson Reuters data.
Abidjan, Cote d’Ivoire, April 2014: FONDS CAURIS CROISSANCE II LIMITED, advised by Cauris Management, the West African fund manager agreed to invest in CIPHARM to fund a new production line for injectable pharmaceutical products.
CIPHARM is a Cote d’Ivoire-based leading pharmaceutical company with revenues derived from 12 countries across west and central Africa. The company has been in operations for over 25 years and manufactures a broad range of generic pharmaceuticals (dry forms, syrups and powder) under its own brand names as well as licensed names.
Fonds Cauris Croissance II Limited’s investment will allow the company to diversify its range of products with injectable pharmaceuticals, for which there is an increasing demand combined with a severe lack of local production. Commenting on this investment, Mr. Ibrahima Diawara, CEO of CIPHARM said: “Fonds Cauris Croissance II investment will help with the launch of new products including hemodialysis solutions, develop new technical partnerships, strengthen governance and an improve relationships with banks”.
“This partnership with CIPHARM is an opportunity for Cauris Management to support a leading pharmaceutical company in its growth and diversification strategy. The economic and population growths in the region generate increased needs for healthcare products and solutions, which need to be delivered with quality and affordable care. Cauris Management will also assist the company in improving its environmental, social and governance standards” notes Mr. Thierry Vissého Gnassounou, Partner at Cauris Management.
The Company is dedicated to the manufacture of OTC nutraceutical products (including herbal medicine) and dietary food supplements, for third-parties only, in solid and liquid forms. Products manufactured vary from powdered mixtures, tablets and capsules to oral liquids, and are available in a variety of packing formats such as bottles, ampoules, vials, blister packaging and foil sachets.
The manufacturing facilities comply with the American and European Manufacturing Practices. It also complies with ISO quality standards, and the electrical design is in accordance with VDE and Spanish government regulations. The facilities could also be used for the production of prescription medication, if necessary.
The Company works with big multinationals from the sector to manufacture their products, which are primarily distributed in health food stores, pharmacies and large retailers.
Advantages for the Investor:
Design and Production: The Company designs and manufactures formulations according to customer’s specifications and is capable of handling all types of requests.
Boasting brand new, first class manufacturing facilities, the Company differentiates itself from competitors as their facilities meet pharmaceutical regulations. The facilities could therefore be easily adapted for the manufacture of prescription medication (however currently only OTC nutraceutical products are made).
Solid Financial and Market Standing:
Figures in EUR millions
Year Turnover EBITDA
2013P 6.67 1.48
2012 6.97 1.20
2011 5.51 0.99
2010 5.25 0.69
SHANGHAI, April 21 (Reuters) – Chinese drugmaker Shanghai Fosun Pharmaceutical Group Co Ltd and private equity firm TPG Capital agreed to buy China-focused Chindex International Inc in a beefed-up $461 million deal after trumping a rival bid. The U.S.-listed healthcare firm signed a sweetened merger agreement after the consortium raised its offer to $24 per share from its original $19.50 per share, Chindex said in a statement late on Monday. An unidentified bidder had offered $23 per share in a “superior proposal” earlier this month.
The rival group declined to bid further, Chindex said. The acquisition will help Fosun Pharmaceutical and TPG increase their access to China’s fast-growing private healthcare market. The government is keen to promote investment in the sector to support overburdened public hospitals and bring prices down through increased competition. China’s healthcare sector is estimated to hit $1 trillion by 2020, according to McKinsey & Co, but is bogged down by rampant corruption, skills shortages and fragmentation.
Chindex runs the premium-end United Family Healthcare hospital chain in China, with operations in major cities such as Beijing, Shanghai, Tianjin and Guangzhou. The offer marked a 4.6 percent premium to Chindex’s Friday close of $22.94. The stock rose 3 percent on Monday.
Fosun Pharmaceutical will invest up to $223.6 million to become the largest shareholder in Chindex International and up to $45 million for a 30 percent stake in its medical equipment supplier unit Chindex Medical Ltd, the Chinese drugmaker said in statement to the Shanghai stock exchange on Monday.
Fosun Pharmaceutical’s bid is subject to approval from its shareholders, although the merger will go ahead regardless of the outcome, Chindex said in its statement. The merger is expected to be completed in the second half of 2014.
In February, Fosun Pharmaceutical and TPG made the initial offer of $369 million to take Chindex private. The deal would see Fosun increase its stake to over 48 percent from around 17 percent now. TPG would hold a similar share, while Chindex founder Roberta Lipson would retain a small stake in the firm.
Fosun Pharmaceutical’s Shanghai-listed shares were up 0.3 percent on Tuesday, ahead of the benchmark CSI 300 Index which was down 0.2 percent.
Chindex International shares were up 3 percent to $23.63 at the close of trading on Monday, and have now risen 35.6 percent this year, far outstripping the benchmark S&P 500 Index, which is up 1.3 percent.
Reuters – U.S. buyout firm KKR & Co LP (KKR.N) has agreed to invest about $200 million in Indian drugmaker Gland Pharma Ltd, marking the largest private equity investment in the local pharmaceutical sector amid growing demand for generic drugs in overseas markets. Continue Reading →
BRUSSELS, Nov 18 (Reuters) – Belgian IBA said on Monday it had completed the sale of its drug discovery arm Cisbio Bioassays business to private equity group Argos Soditic in a deal valuing the business at 25 million euros ($33.7 million). Continue Reading →
FRANKFURT, Nov 8 (Reuters) – Germany’s Boehringer Ingelheim, the world’s largest unlisted drugmaker, is looking to expand its animal health business and is set to make an offer for poultry vaccine and feed additives maker Lohmann Continue Reading →